Australia's largest stock trading and investment forum Australia's #1 stock forum

SNT

2.44%

4.2¢ syntara limited

SNT - Research & Valuation, page-2

First 2 Last

Share
Profile

Follow
ma420

7,254 Posts.

1847

10/07/24

22:49

Post #: 74698887
Share

Originally posted by ma420: ↑

Constellation pharma had a Bromodomain and Extra-Terminal (BET) protein inhibitor called Pelabresib for MF and MDS.

Morphosys acquired Constellation for $1.7Bn in June 2021.
https://www.morphosys.com/en/news/morphosys-acquire-constellation-pharmaceuticals

Next Novartis acquired Morphosys in Feb 2024 for US $2.92 Bn (EUR $2.7 Bn)

https://www.novartis.com/news/media-releases/novartis-strengthen-oncology-pipeline-agreement-acquire-morphosys-ag-eur-68-share-or-aggregate-eur-27bn-cash

The focus of these acquisitions is the combined MF and MDS trial being trialled in combination with JAK inhibitor (Ruxolitinib)- https://clinicaltrials.gov/study/NCT02158858
No.of patients: 336

In the 1/7/24 preso slide 11, Gary has this transaction as successful phase 3- details of the trials here- https://clinicaltrials.gov/study/NCT04603495

Syntara SNT-5505 in MF: https://clinicaltrials.gov/study/NCT04676529
We are also doing a combination trial with the JAK inhibitor ruxolitinib
No.of patients: 39

From the looks of it, Constellation’s and Syntara’s MF trials have similar endpoints (at a high level) although vastly different patient populations.
So yes, at the December readout we may be in the crosshairs of some BPs.

AIMO. DYOR.

Expand

Btw, Platinum asset mgmt were invested in Morphosys prior to the Novartis acquisition. They are likely seeing parallels here and hence invested in Syntara (20%).

SNT Price at posting: 3.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

Making money: How many microcaps should be in an investor's portfolio?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch